Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Incorporation of fluoritnated tryptophan into RV1187

ABSTRACT: Targeted assays were created to monitor the incorporation of fluorinated tryptophan into Rv1187. Assay development was performed on a mixture of labeled and unlabeled Rv1187.

ORGANISM(S): Mycobacterium Tuberculosis

SUBMITTER: Nicole Kruh-Garcia

PROVIDER: PXD010703 | panorama | Tue Mar 09 00:00:00 GMT 2021

REPOSITORIES: PanoramaPublic

ACCESS DATA

Json Xml

Publications

Mechanism of Fluorinated Anthranilate-Induced Growth Inhibition in Mycobacterium tuberculosis.

Nurul Islam M M Hitchings Reese R Kumar Santosh S Fontes Fabio L FL Lott J Shaun JS Kruh-Garcia Nicole A NA Crick Dean C DC

ACS infectious diseases 20181126 1

The biosynthesis of tryptophan in Mycobacterium tuberculosis is initiated by the transformation of chorismate to anthranilate, catalyzed by anthranilate synthase (TrpE/TrpG). Five additional enzymes are required to complete tryptophan biosynthesis. M. tuberculosis strains auxotrophic for tryptophan, an essential amino acid in the human diet, are avirulent. Thus, tryptophan synthesis in M. tuberculosis has been suggested as a potential drug target, and it has been reported that fluorinated anthra ...[more]

PMID: 30406991

Similar Datasets

Circulating Tumor DNA to Monitor the Efficacy of Total Neoadjuvant Therapy for Rectal Cancer

Project description:The purpose of this study is to use the SignateraTm assay created from rectal tumor biopsies to monitor participants’ blood for fragments of DNA shed by tumor cells. The tumor DNA fragments are referred to as circulating tumor DNA, or ctDNA for short.

| 2720974 | ecrin-mdr-crc

The Jules Bordet Institute Molecular Profiling Program Feasibility Trial

Project description:Prior to the use of genomic tests for patient inclusion in clinical trials, it is essential for the Jules Bordet Institute (JBI) to pilot the logistical and technical aspects by examining the feasibility and turnaround time of performing and obtaining data from a few key molecular assays. Patients with metastatic colorectal cancer, non-small cell lung cancer or melanoma will be enrolled. Biopsie from metastatic lesions will be performed. A targeted cancer gene screen assay will be performed using DNA sequencing. Results will be discussed during a molecular screening tumor board.

| 2150838 | ecrin-mdr-crc

Kentucky assay: undecanal bourgeonal mixture

Project description:Kentucky assay: undecanal bourgeonal mixture

| PRJNA509880 | ENA

Monitoring Casbene Synthase in Jatropha curcas Tissues Using Targeted Proteomics

Project description:Casbene synthase is responsible for the first commited step in the biosynthesis of phorbol esters (PE) in the Euphorbiaceae. PE are abundant in the seeds of the biofuel crop Jatropha curcas and its toxicity precludes the use of the protein-rich cake obtained after oil extraction as an animal feed and the toxicity of the fumes derived from burning PE containing biofuel is also a matter of concern. This toxicity is a major hindrance to exploit the potential of this crop as a source of raw material for the production of biodiesel. For this reason, current research on J. curcas is mainly focused in the understanding of the biosynthesis and site of synthesis of PE, as an avenue for the development of biotechnological of genotypes unable to synthesize PE in its seeds. Here, we present the results of targeted proteome assays (SRM and PRM) to monitor and quantify casbene synthase in leaves, endosperma and roots of two J. curcas of contrasting levels of PE. The assays were based in the use of synthetic isotopic labeled peptides derived from 12 gene models of casbene synthase from the J. curcas genome and results showed the presence of casbene synthase encoded in seven of the 12 gene models. Several specific transitions were identified and which can be used to monitor several casbene synthase proteins by any one of the two targeted proteomics assays and/or to validate the results of transcription-based experiments.

2021-09-09 | PXD019525 | Pride

Inserting Pre-Analytical Chromatographic Priming Runs Significantly Improves Targeted Pathway Proteomics With Sample Multiplexing

Project description:GoDig, a platform for targeted pathway proteomics without the need for manual assay scheduling or synthetic standards, is a powerful, flexible, and easy-to-use method that uses tandem mass tags (TMT) to increase sample throughput up to 18-fold relative to label-free methods. Though the protein-level success rates of GoDig are high, the peptide-level success rates are more limited, hampering assays of harder-to-quantify proteins and site-specific phenomena. To guide the optimization of GoDig assays as well as improvements to the GoDig platform, we created GoDigViewer, a new stand-alone software that provides detailed visualizations of GoDig runs. GoDigViewer guided the implementation of “priming runs,” an acquisition mode with significantly higher success rates. In this mode, two or more chromatographic priming runs are automatically performed to improve the accuracy and precision of target elution orders, followed by analytical runs which quantify targets. Using priming runs, success rates exceeded 97% for a list of 400 peptide targets and 95% for a list of 200 targets that are usually not quantified using untargeted mass spectrometry. We used priming runs to establish a quantitative assay of 125 macroautophagy proteins that had a >95% success rate and revealed differences in macroautophagy expression profiles across four human cell lines.

2024-04-12 | PXD051072 | Pride

Screening for candidate clock-controlled genes

Project description:Microarrays were hybridized with a mixture of solutions containing LL2 cDNA labeled with Cy3 or Cy5 (dye-swap) and LL14 cDNA labeled with Cy5 or Cy3 (dye-swap). Keywords: repeat sample

2004-12-29 | GSE2114 | GEO

Elucidating drug mechanistics and resistance in HER2-positive breast cancer cell lines by mathematical modeling

Project description:Advancing precision medicine in the field of cancer is still curbed by the fact that a rational basis to predict treatment outcome is missing. To unravel the mechanism behind targeted drugs (trastuzumab, pertuzumab, erlotinib), mathematical modeling employing ordinary differential equations (ODE) was combined with wet-lab experimentation. Experimentation relied on systematic perturbation experiments to monitor the signaling-response towards drugs in the context of EGF signaling in the HER2+ cell lines SKBR3 and HCC1954.

2016-12-31 | GSE55891 | GEO

CGH of S. meliloti DnaA and Hda overproducing strains

Project description:Assays 1-4: Effects of DnaA activity on S. meliloti chromosome, pSymA and pSymB replicon bias. Sheared DNA extracts of IPTG-induced vs uninduced cultures of DnaA (Assays 1,2) or Hda (Assays 3,4) overexpressors were labeled with Cy3 or Cy5 and hybridized applying dye-swap replicate design. Assay 5: Hybridization of sheared DNA of logarithmic (Cy3-labeled) vs stationary phase (Cy5-labeled) culture.

2015-10-04 | E-MTAB-3924 | biostudies-arrayexpress

Kentucky assay: isoamyl acetate and whiskey lactone mixture

Project description:Kentucky assay: isoamyl acetate and whiskey lactone mixture

| PRJNA509874 | ENA

Clinical Utility of Targeted Next-Generation Sequencing Assay to Detect Copy Number Variants in Myeloid Malignancies: Is It Ready for Prime Time?

Project description:Genetic abnormalities including copy number variants (CNVs, such as gains and losses), and gene mutations are important for diagnosis and treatment of myeloid malignances. In a routine clinical setting, somatic gene mutations are detected by targeted next generation sequencing (NGS), but CNVs are commonly detected by conventional chromosome analysis and fluorescence in situ hybridization (FISH). The aim of this proof-of-principle study was to investigate the feasibility of using a targeted NGS assay to simultaneously detect not only somatic mutations, but also CNVs. Here, we sequenced 406 consecutive patients with myeloid malignancies and performed a head-to-head comparison with the results from conventional clinical assays including conventional chromosome analysis and myeloid FISH to detect CNVs. The targeted NGS assay revealed all 120 CNVs detected by myeloid FISH panel including monosomy 5/5q deletions, monosomy 7/7q deletions, trisomy 8, and 20q deletions. Furthermore, the targeted NGS assay also detected 605 CNVs outsides targeted regions of the myeloid FISH panel, which were revealed by conventional cytogenetic testing. The targeted NGS assay achieved 100% concordance with the myeloid FISH for detection of these common myeloid CNVs, with a high clinical sensitivity (> 99%) and specificity (>99%). The lower limit of detection by the myeloid FISH and the targeted NGS assay was similar and was generally 5% variant allele fraction for DNA. This proof-of-principle study demonstrated that the targeted NGS assay can simultaneously detect both common myeloid CNVs and somatic mutations, which can provide more comprehensive genetic profiling for patients with myeloid malignancies using a single assay.

2021-01-29 | GSE165733 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data